Calidi Biotherapeutics forms Scientific Advisory Board to advance RedTail platform and CLD-401

Calidi Biotherapeutics, Inc.

SAB members include Drs. Mace Rothenberg (ex-Pfizer CMO), Dmitriy Zamarin (Mount Sinai), John Wrangle (MUSC), David Curiel (WashU).
RedTail platform uses enveloped vaccinia virus overexpressing CD55 for systemic delivery of genetic medicines to tumor sites.
Lead candidate CLD-401, in IND-enabling studies, targets NSCLC, head & neck, and other cancers with high unmet need.
CLD-401 is designed to home to metastases, replicate only in tumor cells, and express IL-15 superagonist.
SAB will guide efficient development of CLD-401 into the clinic and advance RedTail platform utility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.